«Similarly 71 drugs approved
by the FDA from 2002 to 2014 for solid tumours have resulted in
median gains in progression - free and
overall survival of only 2.5 and 2.1 months, respectively,» he says adding, «Also, only 42 per cent met the American Society of Clinical Oncology Cancer Research Committee's criteria for meaningful results for patients.»